Perceptive Advisors Q2 2026 Portfolio Activity: Significant Buys and Sells in Biotech Stocks

As of June 30th, 2026, Perceptive Advisors Llc, a significant investment vehicle in the healthcare sector, has shown active portfolio management during this quarter. The total portfolio value stood at approximately $5.08 billion.

The investor's focus appears heavily concentrated within the Healthcare sector, as evidenced by their holdings and changes. This quarter, several companies saw notable shifts in Perceptive Advisors' position:

• RELAY THERAPEUTICS (RLAY) experienced a substantial increase of 44.66%.
• TANGO THERAPEUTICS (TNGX) also significantly boosted its stake by over 300%, specifically increasing by 2,568,847 shares.
• ZYMEWORKS (ZYME) saw a moderate increase of about 19.17% in the quarter.

In contrast to these purchases, Perceptive Advisors also divested from several positions:

• Boston Scientific (BSX), valued at $10.6 million, was sold entirely (-74.46%).
• VIRIDIAN THERAPEUTICS (VRDN) saw a significant reduction of nearly 50%.
• TRAVERE THERAPEUTICS (TVTX) and ROIVANT SCIENCES (G76279101) also experienced notable decreases in their holdings during the quarter.

The overall portfolio allocation remains dominated by Healthcare, accounting for 93.29% of the total value ($4.74 billion). The remaining allocation falls under 'Unknown', representing $340 million or about 6.71% of the portfolio.

These changes reflect a dynamic investment strategy focused on capitalizing on growth opportunities within specific healthcare sub-sectors, while simultaneously exiting positions that may no longer align with their current outlook or valuation criteria.

The investor's activity this quarter involved buying into companies like RELAY THERAPEUTICS and TANGO THERAPEUTICS, potentially seeking exposure to innovative drug development programs. Conversely, they sold out Boston Scientific (BSX) completely and reduced stakes in other smaller healthcare firms such as VRDN.